120 filings
Page 2 of 6
8-K
lnxsri15so476zzmn84v
10 Aug 23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
7:05am
8-K
ta1 7dk7qfm7
5 Jul 23
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
4:09pm
8-K
nvcnm qdmuwgcp
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
8-K
x6xdkjn9ko 2mv
26 Jun 23
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
4:07pm
8-K
6nn8sl
9 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:09pm
8-K
63u85
11 May 23
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
4:06pm
EFFECT
doyczon6genj wjz
8 May 23
Notice of effectiveness
12:15am
CORRESP
udgxe4mi
3 May 23
Correspondence with SEC
12:00am
ARS
gf0e tzp7o2e37tt
24 Apr 23
Annual report to shareholders
4:25pm
DEFA14A
sfl1i2
24 Apr 23
Additional proxy soliciting materials
4:23pm
PRE 14A
u2le7bjy7zxs4vam2wt
14 Apr 23
Preliminary proxy
5:00pm
8-K
bh2kje9qxphe ow
30 Mar 23
Nkarta Announces Departure of Chief Financial & Business Officer
4:11pm
UPLOAD
d08u ft30umpsv9z0g1
21 Mar 23
Letter from SEC
12:00am
8-K
61tryybpc95ki0 x969v
16 Mar 23
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
4:09pm
8-K
1qqtccylis8m
9 Jan 23
Regulation FD Disclosure
4:48pm